Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial

Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial

Background The LoDoCo2 (Low‐Dose Colchicine 2) trial showed that colchicine reduced the risk for cardiovascular events in patients with chronic coronary syndrome. Current guidelines recommend colchicine use in selected high‐risk patients. The aim of this secondary analysis was to explore the relativ...

Full description

Saved in:
Bibliographic Details
Main Authors: Niekbachsh Mohammadnia, Britta E. Wesselink, Willem A. Bax, Stefan M. Nidorf, Arend Mosterd, Aernoud T.L. Fiolet, Aysun Cetinyurek‐Yavuz, Peter L. Thompson, Shrikant I. Bangdiwala, John W. Eikelboom, Jan H. Cornel, Saloua El Messaoudi
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
chronic coronary syndrome
colchicine
risk stratification
secondary prevention
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.038687
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.124.038687

Similar Items